Cargando…
Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside–based low-intensity therapy
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The American Society of Hematology
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9647734/ https://www.ncbi.nlm.nih.gov/pubmed/35201293 http://dx.doi.org/10.1182/bloodadvances.2021006689 |
| _version_ | 1784827439755558912 |
|---|---|
| author | Venugopal, Sangeetha Borthakur, Gautam Daver, Naval DiNardo, Courtney D. Pemmaraju, Naveen Short, Nicholas J. Abbas, Hussein A. Garcia-Manero, Guillermo Konopleva, Marina Ravandi, Farhad Kadia, Tapan M. |
| author_facet | Venugopal, Sangeetha Borthakur, Gautam Daver, Naval DiNardo, Courtney D. Pemmaraju, Naveen Short, Nicholas J. Abbas, Hussein A. Garcia-Manero, Guillermo Konopleva, Marina Ravandi, Farhad Kadia, Tapan M. |
| author_sort | Venugopal, Sangeetha |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9647734 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | The American Society of Hematology |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-96477342022-11-14 Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside–based low-intensity therapy Venugopal, Sangeetha Borthakur, Gautam Daver, Naval DiNardo, Courtney D. Pemmaraju, Naveen Short, Nicholas J. Abbas, Hussein A. Garcia-Manero, Guillermo Konopleva, Marina Ravandi, Farhad Kadia, Tapan M. Blood Adv Research Letter The American Society of Hematology 2022-02-26 /pmc/articles/PMC9647734/ /pubmed/35201293 http://dx.doi.org/10.1182/bloodadvances.2021006689 Text en © 2022 by The American Society of Hematology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| spellingShingle | Research Letter Venugopal, Sangeetha Borthakur, Gautam Daver, Naval DiNardo, Courtney D. Pemmaraju, Naveen Short, Nicholas J. Abbas, Hussein A. Garcia-Manero, Guillermo Konopleva, Marina Ravandi, Farhad Kadia, Tapan M. Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside–based low-intensity therapy |
| title | Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside–based low-intensity therapy |
| title_full | Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside–based low-intensity therapy |
| title_fullStr | Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside–based low-intensity therapy |
| title_full_unstemmed | Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside–based low-intensity therapy |
| title_short | Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside–based low-intensity therapy |
| title_sort | validation of alfa 1200 score in patients with aml >60 years treated with double nucleoside–based low-intensity therapy |
| topic | Research Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9647734/ https://www.ncbi.nlm.nih.gov/pubmed/35201293 http://dx.doi.org/10.1182/bloodadvances.2021006689 |
| work_keys_str_mv | AT venugopalsangeetha validationofalfa1200scoreinpatientswithaml60yearstreatedwithdoublenucleosidebasedlowintensitytherapy AT borthakurgautam validationofalfa1200scoreinpatientswithaml60yearstreatedwithdoublenucleosidebasedlowintensitytherapy AT davernaval validationofalfa1200scoreinpatientswithaml60yearstreatedwithdoublenucleosidebasedlowintensitytherapy AT dinardocourtneyd validationofalfa1200scoreinpatientswithaml60yearstreatedwithdoublenucleosidebasedlowintensitytherapy AT pemmarajunaveen validationofalfa1200scoreinpatientswithaml60yearstreatedwithdoublenucleosidebasedlowintensitytherapy AT shortnicholasj validationofalfa1200scoreinpatientswithaml60yearstreatedwithdoublenucleosidebasedlowintensitytherapy AT abbashusseina validationofalfa1200scoreinpatientswithaml60yearstreatedwithdoublenucleosidebasedlowintensitytherapy AT garciamaneroguillermo validationofalfa1200scoreinpatientswithaml60yearstreatedwithdoublenucleosidebasedlowintensitytherapy AT konoplevamarina validationofalfa1200scoreinpatientswithaml60yearstreatedwithdoublenucleosidebasedlowintensitytherapy AT ravandifarhad validationofalfa1200scoreinpatientswithaml60yearstreatedwithdoublenucleosidebasedlowintensitytherapy AT kadiatapanm validationofalfa1200scoreinpatientswithaml60yearstreatedwithdoublenucleosidebasedlowintensitytherapy |